Laboratoires (ALEMG) | Financial Analysis & Statements
Laboratoires Euromedis S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
38.8M
Total Liabilities
22.3M
Shareholders Equity
16.5M
Debt to Equity
1.35
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Laboratoires Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 36.2M | 34.0M | 54.2M | 111.9M | 193.4M |
| Cost of Goods Sold | 34.3M | 33.9M | 35.4M | 78.4M | 129.3M |
| Gross Profit | 1.9M | 181.7K | 18.7M | 33.5M | 64.2M |
| Gross Margin % | 5.3% | 0.5% | 34.6% | 29.9% | 33.2% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | - | 18.1M | 17.0M |
| Other Operating Expenses | 1.2M | 3.2M | 19.6M | 22.9M | 24.2M |
| Total Operating Expenses | 1.2M | 3.2M | 19.6M | 41.0M | 41.2M |
| Operating Income | 1.3M | -4.3M | -5.4M | 3.7M | 28.7M |
| Operating Margin % | 3.6% | -12.5% | -10.0% | 3.3% | 14.8% |
| Non-Operating Items | |||||
| Interest Income | 590.0K | 27.7M | 18.0K | 43.0K | 177.0K |
| Interest Expense | 502.1K | 359.8K | 365.0K | 345.0K | 457.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 376.7K | 21.7M | -6.0M | 2.5M | 28.5M |
| Income Tax | -3.9K | 269.0K | -41.0K | 210.0K | 5.5M |
| Effective Tax Rate % | -1.0% | 1.2% | 0.0% | 8.4% | 19.4% |
| Net Income | -6.1M | 13.1M | -5.9M | 2.3M | 22.9M |
| Net Margin % | -16.9% | 38.5% | -11.0% | 2.1% | 11.8% |
| Key Metrics | |||||
| EBITDA | 2.0M | 23.5M | -4.2M | 5.1M | 34.0M |
| EPS (Basic) | - | €4.60 | €-1.97 | €0.75 | €7.53 |
| EPS (Diluted) | - | €4.60 | €-1.97 | €0.63 | €6.33 |
| Basic Shares Outstanding | - | 2849001 | 3010488 | 3010488 | 3008738 |
| Diluted Shares Outstanding | - | 2849001 | 3010488 | 3010488 | 3008738 |
Income Statement Trend
Laboratoires Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 15.2M | 18.8M | 26.8M | 31.9M | 15.7M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 7.7M | 8.5M | 8.8M | 14.0M | 24.1M |
| Inventory | 11.9M | 9.6M | 12.6M | 11.8M | 25.7M |
| Other Current Assets | - | - | - | - | 2.0K |
| Total Current Assets | 37.6M | 39.3M | 51.9M | 64.4M | 83.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.4M | 287.1K | 8.2M | 7.5M | 9.8M |
| Goodwill | 189.8K | 4.2M | 5.2M | 5.4M | 7.6M |
| Intangible Assets | 189.8K | 4.2M | 87.0K | 142.0K | 133.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -355 | 2.5K | - | - | - |
| Total Non-Current Assets | 1.1M | 7.0M | 8.0M | 8.3M | 9.3M |
| Total Assets | 38.8M | 46.3M | 59.9M | 72.7M | 92.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 9.5M | 7.8M | 7.3M | 10.5M | 20.7M |
| Short-term Debt | - | - | 3.0K | 541.0K | 1.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | 33.0K | 213.0K | 13.0K |
| Total Current Liabilities | 10.7M | 8.9M | 9.5M | 13.7M | 34.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 8.0M | 10.0M | 12.8M | 15.0M | 16.5M |
| Deferred Tax Liabilities | - | - | 332.0K | 349.0K | 300.0K |
| Other Non-Current Liabilities | 1.6M | 1.5M | 2.0K | 3.0K | - |
| Total Non-Current Liabilities | 11.6M | 14.8M | 15.4M | 17.8M | 19.6M |
| Total Liabilities | 22.3M | 23.7M | 25.0M | 31.5M | 53.7M |
| Equity | |||||
| Common Stock | 5.7M | 5.7M | 6.0M | 6.0M | 6.0M |
| Retained Earnings | -2.2M | 4.2M | -5.9M | 2.3M | 22.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 16.5M | 22.6M | 34.9M | 41.2M | 38.9M |
| Key Metrics | |||||
| Total Debt | 8.0M | 10.0M | 12.8M | 15.5M | 17.8M |
| Working Capital | 27.0M | 30.4M | 42.3M | 50.7M | 49.2M |
Balance Sheet Composition
Laboratoires Cash Flow Statement From 2017 to 2022
| Metric | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -5.9M | 2.3M | 22.9M | -3.6M | -134.0K |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 0 | 0 | 0 | 804.0K | -883.0K |
| Operating Cash Flow | -5.9M | 2.4M | 22.9M | -2.7M | -1.1M |
| Investing Activities | |||||
| Capital Expenditures | -1.0M | -1.4M | -653.0K | -1.4M | 8.0K |
| Acquisitions | - | - | - | - | -341.0K |
| Investment Purchases | - | - | - | - | -60.0K |
| Investment Sales | 22.0K | 434.0K | 61.0K | - | - |
| Investing Cash Flow | -1.1M | -1.1M | -592.0K | -1.2M | -734.0K |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | 36.0K |
| Dividends Paid | - | - | - | - | -269.0K |
| Debt Issuance | - | - | 20.0M | 11.8M | 1.1M |
| Debt Repayment | -2.2M | -1.3M | -10.6M | -8.4M | -1.0M |
| Financing Cash Flow | -2.1M | -1.3M | 9.4M | 3.4M | -52.0K |
| Free Cash Flow | -2.1M | 17.4M | 12.8M | -2.3M | -232.0K |
| Net Change in Cash | -9.1M | -34.0K | 31.7M | -490.0K | -1.9M |
Cash Flow Trend
Laboratoires Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
12.79
Forward P/E
11.14
Price to Book
0.84
Price to Sales
0.36
PEG Ratio
11.14
Profitability Ratios
Profit Margin
-14.19%
Operating Margin
-0.26%
Return on Equity
-28.35%
Return on Assets
1.32%
Financial Health
Current Ratio
1.84
Debt to Equity
50.72
Beta
0.43
Per Share Data
EPS (TTM)
€0.38
Book Value per Share
€5.80
Revenue per Share
€12.64
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALEMG | 13.9M | 12.79 | 0.84 | -28.35% | -14.19% | 50.72 |
| Bastide le Confort | 182.0M | 19.92 | 1.80 | 11.56% | 5.77% | 316.42 |
| Metrics In Balance | 144.9K | - | 0.01 | 0.08% | 30.13% | - |
Financial data is updated regularly. All figures are in the company's reporting currency.